Search: onr:"swepub:oai:gup.ub.gu.se/43454" >
Topoisomerase II in...
Topoisomerase II inhibitors, irrespective of their chemical composition, ameliorate experimental arthritis
-
- Verdrengh, Margareta, 1942 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för reumatologi och inflammationsforskning,Institute of Internal Medicine, Dept of Rheumatology and Inflammation Research
-
- Isaksson, Olle, 1943 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin,Institute of Internal Medicine
-
- Tarkowski, Andrej, 1951 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för reumatologi och inflammationsforskning,Institute of Internal Medicine, Dept of Rheumatology and Inflammation Research
-
(creator_code:org_t)
- 2004-10-19
- 2005
- English.
-
In: Rheumatology (Oxford). - : Oxford University Press (OUP). - 1462-0324 .- 1462-0332. ; 44:2, s. 183-6
- Related links:
-
https://academic.oup...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- OBJECTIVE: Rheumatoid arthritis (RA) is an autoimmune disease, characterized by a chronic inflammation in the joints. The model of collagen-induced arthritis (CIA) has been extensively used to elucidate the pathogenic mechanisms relevant to human RA and is widely employed for the evaluation of potential anti-rheumatic agents. Etoposide and mitoxantrone are immunosuppressive drugs, both acting by inhibiting the topoisomerase II function. We have previously demonstrated an ameliorating effect of etoposide in CIA. The aims of this study were (1) to assess the optimal ameliorating dose of etoposide and (2) to ascertain that topoisomerase II inhibition, irrespective of the chemical composition of the drug, affects the course of autoimmunity. METHODS: Male DBA/1 mice were treated with 12.5 mg/kg body weight of etoposide five times, twice, once per week or once every second week. Mitoxantrone was administered as high dose (1 mg/kg body weight five times after immunization or after booster with collagen II) or low dose (3 microg/mouse, 5 days/week starting after collagen II immunization or after booster). RESULTS: Treatment with 12.5 mg/kg body weight five times or twice weekly with etoposide completely inhibited development of arthritis. Low-dose treatment with mitoxantrone after collagen II immunization or high-dose treatment after collagen II booster delayed the onset of arthritis. These results were observed clinically as well as histologically. In addition, serum levels of anti-collagen II antibodies were significantly lower in mice displaying less severe arthritis. CONCLUSION: Treatment of collagen-induced arthritis with topoisomerase II inhibitors ameliorates the development of disease.
Keyword
- Animals
- Antibody Formation/drug effects
- Arthritis
- Experimental/*drug therapy
- Arthritis
- Rheumatoid/*drug therapy
- Collagen Type II/immunology
- DNA Topoisomerases
- Type II/*antagonists & inhibitors
- Dose-Response Relationship
- Drug
- Down-Regulation
- Etoposide/*therapeutic use
- Immunization/methods
- Immunosuppressive Agents/therapeutic use
- Interleukin-6/blood
- Male
- Mice
- Mice
- Inbred DBA
- Mitoxantrone/*therapeutic use
- Nucleic Acid Synthesis Inhibitors/*therapeutic use
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database